← Back to Search

Cannabinoid

CBD Oil for Stress Related to COVID-19 (CBDOIL Trial)

Phase 2 & 3
Recruiting
Led By Michael J Telch, Ph.D.
Research Sponsored by University of Texas at Austin
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up week 5-follow-up

Summary

This trial will compare the effects of CBD isolate, full-spectrum CBD oil, broad-spectrum CBD oil, and placebo oil on reducing stress caused by COVID-19.

Who is the study for?
Adults aged 18-70 with COVID-19 related stress, anxiety, depression, anger, substance use issues or sleep disturbances can join. They must be fluent in English, have internet at home and agree to only use study products for 6 weeks. Pregnant individuals or those with certain medical conditions like liver disease or on specific medications cannot participate.
What is being tested?
The trial is testing the effects of three types of CBD oil (isolate, full spectrum, broad-spectrum) versus a placebo oil on emotional distress caused by COVID-19. Participants will receive one of these treatments randomly and their symptoms will be monitored.
What are the potential side effects?
Potential side effects are not detailed here but could include reactions similar to known CBD responses such as fatigue, changes in appetite or mood swings. Allergic reactions may occur especially if sensitive to coconut oil used as a carrier.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~week 5-follow-up
This trial's timeline: 3 weeks for screening, Varies for treatment, and week 5-follow-up for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
PROMIS Emotional Distress Index
Secondary study objectives
COVID-19 Coping Self-Efficacy
PROMIS Alcohol Negative Consequences Scale
PROMIS Anger Scale
+4 more

Trial Design

4Treatment groups
Active Control
Placebo Group
Group I: Broad-Spectrum CBD oil 300 mg.Active Control1 Intervention
Nightly oral administration of 300 mg. of Broad-Spectrum CBD Oil for 28 consecutive days
Group II: Full-Spectrum CBD Oil 300 mg.Active Control1 Intervention
Nightly oral administration of 300 mg. of Full Spectrum CBD Oil for 28 consecutive days
Group III: CBD-Isolate 300 mg.Active Control1 Intervention
Nightly oral administration of 300 mg. of CBD-Isolate for 28 consecutive days
Group IV: Placebo OilPlacebo Group1 Intervention
Nightly oral administration of 300 mg. of Placebo Oil for 28 consecutive days

Find a Location

Who is running the clinical trial?

University of Texas at AustinLead Sponsor
374 Previous Clinical Trials
85,975 Total Patients Enrolled
Way West WellnessUNKNOWN
SunFlora.IncUNKNOWN
1 Previous Clinical Trials
29 Total Patients Enrolled

Media Library

Broad-Spectrum CBD Oil (Cannabinoid) Clinical Trial Eligibility Overview. Trial Name: NCT04603781 — Phase 2 & 3
Substance Abuse Research Study Groups: Broad-Spectrum CBD oil 300 mg., Placebo Oil, Full-Spectrum CBD Oil 300 mg., CBD-Isolate 300 mg.
Substance Abuse Clinical Trial 2023: Broad-Spectrum CBD Oil Highlights & Side Effects. Trial Name: NCT04603781 — Phase 2 & 3
Broad-Spectrum CBD Oil (Cannabinoid) 2023 Treatment Timeline for Medical Study. Trial Name: NCT04603781 — Phase 2 & 3
Substance Abuse Patient Testimony for trial: Trial Name: NCT04603781 — Phase 2 & 3
~41 spots leftby Nov 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top